Net Cash Provided by (Used in) Financing Activities in USD of NEKTAR THERAPEUTICS from Q1 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Nektar Therapeutics quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2010 to Q1 2025.
  • Nektar Therapeutics Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was $7K.
  • Nektar Therapeutics annual Net Cash Provided by (Used in) Financing Activities for 2024 was $42.1M.
  • Nektar Therapeutics annual Net Cash Provided by (Used in) Financing Activities for 2023 was $30K.
  • Nektar Therapeutics annual Net Cash Provided by (Used in) Financing Activities for 2022 was $1.51M, a 95.8% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

NEKTAR THERAPEUTICS Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $7K* -$42M Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-09
Q1 2024 $42M +$42M Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-09
Q1 2023 $0 -$938K -100% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-10
Q1 2022 $938K -$16.9M -94.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q1 2021 $17.9M +$6.78M +61.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q1 2020 $11.1M +$6.18M +126% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q1 2019 $4.89M -$29.5M -85.8% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q1 2018 $34.4M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q1 2013 -$2.47M -$122M -102% Jan 1, 2013 Mar 31, 2013 10-Q 2013-05-09
Q1 2012 $120M -$102M -46% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-09
Q1 2011 $221M +$217M +4915% Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-04
Q1 2010 $4.42M Jan 1, 2010 Mar 31, 2010 10-Q 2011-04-29

NEKTAR THERAPEUTICS Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $42.1M +$42.1M Jan 1, 2024 Dec 31, 2024 10-K 2025-03-14
2023 $30K* -$1.48M Jan 1, 2023 Dec 31, 2023 10-K 2025-03-14
2022 $1.51M -$34.7M -95.8% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-05
2021 $36.2M +$117M Jan 1, 2021 Dec 31, 2021 10-K 2024-03-05
2020 -$80.4M -$104M -444% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-28
2019 $23.4M -$829M -97.3% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-01
2018 $852M +$798M +1466% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-26
2017 $54.4M -$149M -73.3% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-28
2016 $204M Jan 1, 2016 Dec 31, 2016 10-K 2019-03-01
2013 $2.22M -$24.6M -91.7% Jan 1, 2013 Dec 31, 2013 10-K 2014-02-27
2012 $26.8M -$196M -87.9% Jan 1, 2012 Dec 31, 2012 10-K 2014-02-27
2011 $222M +$215M +2851% Jan 1, 2011 Dec 31, 2011 10-K 2014-02-27
2010 $7.54M Jan 1, 2010 Dec 31, 2010 10-K 2013-03-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.